Xenetic Biosciences Inc(XBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XBIO Xenetic Biosciences Inc

Closed 10-30 16:00:00 EDT

2.05

-0.07

-3.30%

盘后2.05

+0.000.00%

19:53 EDT

High2.15	Low1.95	Vol32.62K
Open2.14	D1 Closing2.12	Amplitude9.43%
Mkt Cap4.80M	Tradable Cap4.05M	Total Shares2.34M
T/O67.12K	T/O Rate1.65%	Tradable Shares1.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XBIO","market":"US","secType":"STK","nameCN":"Xenetic Biosciences Inc","latestPrice":2.05,"timestamp":1793390400000,"preClose":2.12,"halted":0,"volume":32616,"hourTrading":{"tag":"盘后","latestPrice":2.05,"preClose":2.05,"latestTime":"19:53 EDT","volume":55,"amount":111.57,"timestamp":1793404434384,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03301886792452843,"floatShares":1975362,"shares":2343181,"eps":-1.19,"marketStatus":"Closed","change":-0.07,"latestTime":"10-30 16:00:00 EDT","open":2.14,"high":2.15,"low":1.95,"amount":67118.0071536,"amplitude":0.09434,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.19,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793610000000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.12,"preHourTrading":{"tag":"盘前","latestPrice":2.0781,"preClose":2.12,"latestTime":"08:46 EDT","volume":757,"amount":1573.8273754,"timestamp":1793364393068,"change":-0.0419,"changeRate":-0.019764,"amplitude":0.011557},"postHourTrading":{"tag":"盘后","latestPrice":2.05,"preClose":2.05,"latestTime":"19:53 EDT","volume":55,"amount":111.57,"timestamp":1793404434384,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.645843,"impliedVol":2.5089,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/XBIO/tweets","defaultTab":"tweets","newsList":[{"id":"2675582088","title":"Xenetic Reports First Patient Dosed in DNase-CAR T Combination Study for Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2675582088","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675582088?lang=en_us&edition=fundamental","pubTime":"2026-10-15 20:46","pubTimestamp":1792068393,"startTime":"0","endTime":"0","summary":"Xenetic Reports First Patient Dosed in DNase-CAR T Combination Study for Large B-Cell LymphomaXenetic Biosciences announced the first patient was dosed in a study combining systemic DNase with CAR T-c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261015:nNDL1KKXhD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668531938","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2668531938","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668531938?lang=en_us&edition=fundamental","pubTime":"2026-09-17 02:53","pubTimestamp":1789584803,"startTime":"0","endTime":"0","summary":"J.B. Hunt Transport Services  expects earnings to fall 5% to 10% sequentially in Q3, Chief Financial Officer Brad Delco said Tuesday on a conference call. The company faced \"one of the most acute changes in the cost of purchased transportation,\" with intra-quarter spot rates rising 30%, Delco said.Shares slumped 13% as intraday trading volume catapulted to over 3.33 million from a daily average of about 949,000.Xenetic Biosciences  has entered into a definitive agreement to acquire all outstanding shares of Santersus in an all-stock transaction. The combined company is expected to continue trading on the Nasdaq Capital Market as Santersus Bio under a new ticker symbol, \"SNTS.\"Shares sank 50% as intraday trading volume soared to over 1.32 million from the stock's daily average of roughly 41,000.Price: 238.97, Change: -34.09, Percent Change: -12.48","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JBHT","BK4520","XBIO","BK4232","BK4139","BK4022","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667948600","title":"Xenetic, Santerus enter definitive share exchange agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2667948600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667948600?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:10","pubTimestamp":1789557021,"startTime":"0","endTime":"0","summary":"Xenetic (XBIO) Biosciences and Santersus announced that they have entered into a definitive share exchange agreement pursuant to which Xenetic will...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenetic-santerus-enter-definitive-share-exchange-agreement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenetic-santerus-enter-definitive-share-exchange-agreement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667070216","title":"Xenetic Biosciences: Santersus Shareholders to Own About 85% of Combined Co Post-Closing - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2667070216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667070216?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:06","pubTimestamp":1789556775,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN458043:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607787","title":"Xenetic Biosciences Agrees to Acquire Santersus in All-Stock Share Exchange Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607787","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607787?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:02","pubTimestamp":1789556531,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences agrees to acquire Santersus in all-stock share exchange dealXenetic Biosciences will acquire privately held Santersus in an all-stock share exchange, subject to shareholder approva","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL1LLTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607296","title":"Xenetic Biosciences Inc: Deal Expected to Create NASDAQ-Listed, Multi-Indication Clinical-Stage Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607296","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607296?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556493,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4570UD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607284","title":"Xenetic Biosciences Inc: Co & Santersus Ag Announce Definitive Share Exchange Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607284","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607284?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556493,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4570UD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667298607","title":"Xenetic Biosciences: Combined Co Expected to Continue to Trade on NASDAQ Capital Market as Santersus Bio, Inc. Under New Ticker Symbol \"Snts\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2667298607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667298607?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556493,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4570UD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607953","title":"NASDAQ Trade Halt Halt News Pending at 06:55 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607953","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607953?lang=en_us&edition=fundamental","pubTime":"2026-09-16 18:55","pubTimestamp":1789556100,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 06:55 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nAQN2MJF4Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645729","title":"Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645729","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645729?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:44","pubTimestamp":1786106668,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences Q2 royalty revenue rises on Takeda sublicenseOverviewUS biopharma firm's Q2 royalty revenue rose 12% yr/yr, driven by Takeda sublicenseQ2 net loss widened to $0.9 mln from $0.7 mln","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHE","BK4007","BK4139","RPRX","XBIO","XNCR","PBE","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657173645","title":"Xenetic Biosciences Q2 Net Income USD -900 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2657173645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657173645?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:35","pubTimestamp":1786106101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nPLXXCCQ3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657662096","title":"Xenetic Biosciences Q2 FY26 Net Loss Widens 35% to $929,695; Revenue Rises 12% to $660,601","url":"https://stock-news.laohu8.com/highlight/detail?id=2657662096","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657662096?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:55","pubTimestamp":1786053316,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences Q2 FY26 net loss widens 35% to $929,695; revenue rises 12% to $660,601Xenetic Biosciences posted a GAAP net loss of USD 929,695 for the quarter ended June 30, 2026, widening 35% ye","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL65CSs6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157037","title":"Xenetic partner wins Israeli health ministry clearance for DNase I plus anti-CD19 CAR-T lymphoma study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157037","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157037?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:41","pubTimestamp":1780576861,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences’ partner PeriNess secured Israeli Health Ministry clearance for an investigator-initiated DNase I plus anti-CD19 CAR T study in LBCL.Trial targets 12 patients with stable or progressive disease at lymphodepletion, aiming to test whether DNase I improves CAR T expansion and response.Study will run at Tel-Aviv Sourasky Medical Center, with initial efficacy readouts planned at 1 and 3 months post-infusion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDLb7QQm9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640695791","title":"Xenetic announces preclinical data on DNase I at ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640695791","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640695791?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:58","pubTimestamp":1780322330,"startTime":"0","endTime":"0","summary":"Xenetic (XBIO) Biosciences announced positive preclinical data will be presented at the 2026 American Society of Clinical Oncology, ASCO, Annual Me...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenetic-announces-preclinical-data-on-dnase-i-at-asco-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenetic-announces-preclinical-data-on-dnase-i-at-asco-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954274","title":"Xenetic Biosciences posts ASCO 2026 data showing DNase I boosts CAR-T persistence in B-cell cancer models","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954274","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640954274?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:05","pubTimestamp":1780319102,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences highlighted positive preclinical data on DNase I as an add-on to CAR-T therapy at ASCO 2026 on June 1.Results were presented as a poster on June 1, 2026, with findings positioned to support continued clinical development.Studies showed DNase I improved CAR-T cell durability, limited functional decline, strengthened tumor control, and extended survival versus CAR-T alone.Translational observations in a pediatric refractory Burkitt lymphoma case linked DNase I co-administration to renewed CAR-T expansion and tumor reduction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL35YSkg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635572784","title":"Xenetic Biosciences Q1 Net Income USD -500 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2635572784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635572784?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:05","pubTimestamp":1778673900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLX5E91F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635400362","title":"Xenetic Biosciences Q1 net loss narrows 49.5% to $456,382","url":"https://stock-news.laohu8.com/highlight/detail?id=2635400362","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635400362?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:33","pubTimestamp":1778617982,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences posted a net loss of USD 456,382 for quarter ended March 31, 2026, narrowing 49.5%.Revenue rose 36% to USD 806,923, driven by higher royalty revenue.Operating loss narrowed 46.7% to USD 502,117 as operating costs and expenses fell 14.8% to USD 1.31 million.Research and development expense dropped 24.8% to USD 661,443, while general and administrative expense edged down 1.4% to USD 647,597.Board launched a formal strategic review that includes options such as a sale of the company or assets, a business combination, or a reverse merger, while continuing to advance its systemic DNase program toward the clinic.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2z28rP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630820336","title":"Xenetic grants interim CEO, CFO James Parslow 100,000 restricted shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2630820336","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630820336?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:01","pubTimestamp":1777064476,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences granted Interim CEO and CFO James Parslow 100,000 restricted shares under its Amended and Restated Equity Incentive Plan.Vesting starts with 7,000 shares on April 21, 2026.Remaining 93,000 shares vest in three equal tranches on first, second, third anniversaries of April 21, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL1tb6X9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629044593","title":"Xenetic abstract on DNase I boosting CAR-T efficacy accepted for ASCO presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2629044593","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629044593?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:11","pubTimestamp":1776863462,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences announced acceptance of a preclinical immuno-oncology abstract for presentation at 2026 ASCO Annual Meeting.Data will be presented June 1, 2026, in a poster session in Chicago.Research supports a DNase I approach targeting cfDNA and NETs to boost CAR T-cell function, aiming to improve antitumor activity.Update signals continued development of Xenetic’s DNase-based platform, positioning it as a potential enhancer for CAR T therapies in hard-to-treat cancers.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLbBzdmm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xeneticbio.com","stockEarnings":[{"period":"1week","weight":0.0984},{"period":"1month","weight":-0.0619},{"period":"3month","weight":-0.1637},{"period":"6month","weight":-0.2862},{"period":"1year","weight":-0.3801},{"period":"ytd","weight":-0.023}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.0068},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.0676},{"period":"1year","weight":0.1192},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.202562},{"month":2,"riseRate":0.4,"avgChangeRate":-0.047313},{"month":3,"riseRate":0.4,"avgChangeRate":-0.081225},{"month":4,"riseRate":0.6,"avgChangeRate":-0.012383},{"month":5,"riseRate":0.4,"avgChangeRate":-0.114779},{"month":6,"riseRate":0.8,"avgChangeRate":0.234254},{"month":7,"riseRate":0.6,"avgChangeRate":0.028803},{"month":8,"riseRate":0.3,"avgChangeRate":-0.055837},{"month":9,"riseRate":0.3,"avgChangeRate":-0.129289},{"month":10,"riseRate":0.3,"avgChangeRate":-0.087},{"month":11,"riseRate":0.555556,"avgChangeRate":0.039534},{"month":12,"riseRate":0.4,"avgChangeRate":-0.011037}],"exchange":"NASDAQ","name":"Xenetic Biosciences Inc","nameEN":"Xenetic Biosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenetic Biosciences Inc(XBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xenetic Biosciences Inc(XBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xenetic Biosciences Inc,XBIO,Xenetic Biosciences Inc股票,Xenetic Biosciences Inc股票老虎,Xenetic Biosciences Inc股票老虎国际,Xenetic Biosciences Inc行情,Xenetic Biosciences Inc股票行情,Xenetic Biosciences Inc股价,Xenetic Biosciences Inc股市,Xenetic Biosciences Inc股票价格,Xenetic Biosciences Inc股票交易,Xenetic Biosciences Inc股票购买,Xenetic Biosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenetic Biosciences Inc(XBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xenetic Biosciences Inc(XBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction